Joseph Tucker, PhD, CEO of Enveric Biosciences, Naples, FL, explains the ‘PsyAI’ artificial intelligence system. This AI filters through Enveric’s ‘Psybrary’ of millions of novel synthetic drug candidates to select the most ideal candidates for each new target.
This video presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors. A discussion of these factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.